Crisaborole Ointment Improves Quality of Life of Patients with Mild to Moderate Atopic Dermatitis and Their Families

ConclusionCrisaborole treatment results in clinically meaningful improvement in QoL for patients and their parents/caregivers/families.Trial RegistrationAD-301:http://www.clinicaltrials.gov, NCT02118766; AD-302:http://www.clinicaltrials.gov, NCT02118792.FundingAnacor Pharmaceuticals, Inc., a wholly owned subsidiary of Pfizer Inc., New York, NY.
Source: Dermatology and Therapy - Category: Dermatology Source Type: research